{"links":{"html":"https://www.erudio.com/reports/keynote-867-nct03924869","json":"https://www.erudio.com/reports/keynote-867-nct03924869.json","markdown":"https://www.erudio.com/reports/keynote-867-nct03924869.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"keynote-867-03924869"}},"request":"https://www.erudio.com/contact?report=keynote-867-03924869"},"offer":{"cited_commentary_sources":55,"verified_hcp_statements":258,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":66,"optional":true,"price_per_verified_person_usd":15,"price_usd":990,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"keynote-867-nct03924869"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=keynote-867-03924869","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/keynote-867-nct03924869","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T08:17:11.073889Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":0},"aspects":[{"claim_count":10,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Event-free Survival (EFS)"},{"claim_count":11,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":11,"title":"Secondary endpoints"},{"claim_count":39,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":16,"title":"Population and setting"},{"claim_count":29,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":13,"title":"The comparison"},{"claim_count":20,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":27,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":21,"title":"Design and conduct"},{"claim_count":28,"coverage":"discussed","id":"A1","source_count":13,"title":"Phase II–phase III discordance and the awaited PACIFIC-4/PACIFIC-IV result"},{"claim_count":18,"coverage":"discussed","id":"A2","source_count":9,"title":"Duration, treatment burden and salvage-treatment controls"},{"claim_count":11,"coverage":"discussed","id":"A3","source_count":10,"title":"Biomarkers, residual disease risk and personalized treatment"},{"claim_count":11,"coverage":"discussed","id":"A4","source_count":3,"title":"Anatomy, fractionation and alternatives when SBRT is unsuitable"},{"claim_count":31,"coverage":"discussed","id":"A5","source_count":7,"title":"Operable treatment choices and the validity of SBRT–surgery comparisons"},{"claim_count":27,"coverage":"discussed","id":"A6","source_count":3,"title":"Early-stage cure optimization, dissemination and the limits of surrogate signals"},{"claim_count":21,"coverage":"discussed","id":"A7","source_count":6,"title":"Radiation–immune biology and exploratory combination strategies"},{"claim_count":11,"coverage":"discussed","id":"A8","source_count":7,"title":"Access, recruitment, affordability and support after treatment discontinuation"},{"claim_count":8,"coverage":"discussed","id":"A9","source_count":4,"title":"Endpoint ascertainment, clinical relevance and limits of further planned evidence"}],"counts":{"cited_sources":57,"claims_by_expression_type":{"comparison":26,"experience":8,"interpretation":54,"opinion":69,"primary_context":18,"question":32,"restatement":19,"uncertainty":14,"unspecified":18},"claims_by_kind":{"counterview":3,"interpretation":2,"protocol_statement":11,"publication_statement":1,"source_observation":241},"clinician_statements":178,"evidence_units":268,"findings":12,"organisational_accounts":5,"people_cited":72,"people_identity_verified":66,"people_total":72,"screened_sources":96,"verified_claims":258},"findings_index":[{"id":"F1","structure":{"claims":18,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":2,"views":12},"has_counterview":true,"limitations":2,"links":{"context":1,"support":19},"ma_question":true,"named_voices":12,"passages":16,"sources":12,"sources_by_kind":{"commentary":9,"media":1,"publication":1,"registry":1}},"title":"Restraint in routine immunotherapy addition is the leading clinical reading, but its scope matters"},{"id":"F2","structure":{"claims":25,"claims_by_group":{"comparisons":2,"experience":4,"questions":4,"restated":1,"views":14},"has_counterview":true,"limitations":2,"links":{"context":2,"support":25},"ma_question":true,"named_voices":11,"passages":24,"sources":11,"sources_by_kind":{"commentary":9,"media":2}},"title":"Frailty, competing mortality and strong local control explain why some clinicians would withhold additional treatment"},{"id":"F3","structure":{"claims":18,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":3,"views":11},"has_counterview":true,"limitations":2,"links":{"context":2,"support":18},"ma_question":true,"named_voices":9,"passages":17,"sources":9,"sources_by_kind":{"commentary":7,"media":1,"registry":1}},"title":"Concurrent treatment is challenged more strongly than all possible radiation–immunotherapy sequencing"},{"id":"F4","structure":{"claims":18,"claims_by_group":{"comparisons":2,"experience":0,"questions":5,"restated":4,"views":7},"has_counterview":true,"limitations":3,"links":{"context":1,"support":19},"ma_question":true,"named_voices":14,"passages":18,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"Duration is an independent concern about burden, toxicity, incentives and trial controls"},{"id":"F5","structure":{"claims":25,"claims_by_group":{"comparisons":7,"experience":0,"questions":6,"restated":0,"views":12},"has_counterview":true,"limitations":2,"links":{"context":1,"support":25},"ma_question":true,"named_voices":19,"passages":25,"sources":13,"sources_by_kind":{"commentary":13}},"title":"Discordant phase II and phase III findings generate both methodological skepticism and continued optimism"},{"id":"F6","structure":{"claims":13,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":5,"views":4},"has_counterview":true,"limitations":4,"links":{"context":0,"support":13},"ma_question":true,"named_voices":6,"passages":13,"sources":5,"sources_by_kind":{"commentary":3,"media":1,"registry":1}},"title":"EFS interpretation is disputed, including whether imaging changes were mistaken for progression"},{"id":"F7","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":2,"views":4},"has_counterview":true,"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":7,"passages":10,"sources":9,"sources_by_kind":{"commentary":8,"registry":1}},"title":"Selection and personalization remain open questions, including alternatives to adding IO to SBRT"},{"id":"F8","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":1,"questions":2,"restated":2,"views":4},"has_counterview":false,"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":3,"passages":6,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Local-treatment suitability and anatomy qualify any discussion of adding systemic therapy"},{"id":"F9","structure":{"claims":31,"claims_by_group":{"comparisons":6,"experience":1,"questions":2,"restated":1,"views":21},"has_counterview":true,"limitations":3,"links":{"context":1,"support":31},"ma_question":true,"named_voices":13,"passages":25,"sources":7,"sources_by_kind":{"commentary":6,"media":1}},"title":"The result does not resolve surgery versus SBRT in fit patients, despite strong opinions about that choice"},{"id":"F10","structure":{"claims":27,"claims_by_group":{"comparisons":2,"experience":1,"questions":5,"restated":9,"views":10},"has_counterview":true,"limitations":3,"links":{"context":0,"support":29},"ma_question":true,"named_voices":7,"passages":27,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Earlier cure-optimization debates include emphatic but contested claims about dissemination and surrogate signals"},{"id":"F11","structure":{"claims":21,"claims_by_group":{"comparisons":0,"experience":1,"questions":7,"restated":1,"views":12},"has_counterview":true,"limitations":3,"links":{"context":2,"support":21},"ma_question":true,"named_voices":10,"passages":20,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Mechanistic explanations remain disputed, with exploratory alternatives rather than demonstrated rescue strategies"},{"id":"F12","structure":{"claims":12,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":7,"views":2},"has_counterview":true,"limitations":3,"links":{"context":1,"support":14},"ma_question":true,"named_voices":7,"passages":11,"sources":8,"sources_by_kind":{"commentary":6,"media":1,"registry":1}},"title":"Access, recruitment and support for affected patients are distinct from efficacy interpretation"}],"medical_affairs_question":"What evidence would justify moving from routine restraint to a selected, tolerable systemic-treatment strategy after or around SBRT?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. Routine intensification: a clinical boundary, not a universal class verdict"},{"id":"section-2","level":2,"title":"2. Who could benefit enough—and tolerate enough—to justify more treatment?"},{"id":"section-3","level":2,"title":"3. Timing: concern about concurrent exposure, with sequential approaches still investigational"},{"id":"section-4","level":2,"title":"4. Duration, burden and the fairness of control treatment"},{"id":"section-5","level":2,"title":"5. Phase II promise versus phase III confirmation—and what to make of PACIFIC-IV"},{"id":"section-6","level":2,"title":"6. EFS: uncertainty about measurement is not proof of misclassification"},{"id":"section-7","level":2,"title":"7. Biomarkers, operability and personalized regimens remain questions"},{"id":"section-8","level":2,"title":"8. The SBRT backbone itself requires selection and safe delivery"},{"id":"section-9","level":2,"title":"9. Surgery versus SBRT: preserve the standard-of-care view and the objection to its evidentiary basis"},{"id":"section-10","level":2,"title":"10. Cure optimization and dissemination: preserve the emphatic views and the surrogate caveats"},{"id":"section-11","level":2,"title":"11. Biology: asserted immunosuppression, uncertain abscopal relevance and druggable feedback"},{"id":"section-12","level":2,"title":"12. Participation, affordability and what patients need after discontinuation"},{"id":"section-13","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F6","shared_claims":6}],"id":"T1","label":"Primary endpoint: Event-free Survival (EFS)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F9","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":22},{"id":"F3","shared_claims":1},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":1},{"id":"F9","shared_claims":4}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":15},{"id":"F4","shared_claims":13},{"id":"F5","shared_claims":2},{"id":"F11","shared_claims":1},{"id":"F12","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F3","shared_claims":2},{"id":"F5","shared_claims":9},{"id":"F6","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T08:17:11.073889Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T08:29:31Z","record_hash":"5932527c8a13b7d676cb0816674e3667bc27936d8c3e1e3dbed99067c14f4506","release_hash":"4acb74440eaf5e4a596a2f749d139eb1165c464027c03d5ec32f7db85de65111","report_id":"erudio-nct03924869","run_id":"d328baeb-3135-408e-80f0-cb8d714d7372","schema_version":"5.0","slug":"keynote-867-03924869","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"KEYNOTE-867 asks whether adding pembrolizumab to stereotactic body radiotherapy improves outcomes in unresected stage I–II non-small cell lung cancer. Commentary comes from X and LinkedIn posts and physician contributions on YouTube. Debate centers on whether pembrolizumab should be added routinely and how event-free survival should be interpreted, with the endpoint’s meaning contested. Discordant phase II and phase III findings also divide expectations for further SBRT–immunotherapy research.","meta_description":"96 sources screened · 258 verified statements (178 from clinicians verified by NPI or staff page) from 57 sources · 12 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-cf4e7a98080819a51d19","claim-307caea9846c1948b96d"],"id":"F5","paraphrase":"An X-thread exchange asked how KEYNOTE-867 and I-SABR differed in their trial designs.","publication_caveats":{"reason":"Publication caveats are not stated for the cited X threads.","status":"not_set"},"source_channel":"x_thread","source_date":"2024-08-29","title":"Discordant phase II and phase III findings generate both methodological skepticism and continued optimism"},{"cited_claim_ids":["claim-462f28c2369fdec479c5","claim-f0fb34fd400050ed63ec","claim-0af06536cf580dab77c4"],"id":"F6","paraphrase":"An X-thread exchange asked how event-free survival was defined in KEYNOTE-867 and whether that endpoint reflected routine clinical care.","publication_caveats":{"reason":"Publication caveats are not stated for this X thread.","status":"not_set"},"source_channel":"x_thread","source_date":"2024-12-13","title":"EFS interpretation is disputed, including whether imaging changes were mistaken for progression"}]},"publication":{"approved_at":"2026-10-31T08:29:31Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":96},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a remark on studying upfront alternatives to surgery to optimize cure in stage I lung cancer.","Not yet captured in this edition: a view on uncertainty over adjuvant versus salvage immunotherapy and similar trial designs in unresected early-stage lung cancer.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","116 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing.","The report describes the sources reviewed for this edition, not all public discussion or the frequency of opinions among HCPs. Trial-name-focused source selection may miss unnamed references and transcription variants.","Some potentially relevant passages were not fully assessed. Portions of the salvage-control, treatment-duration and financial-burden discussion may contain additional reasons or qualifications not represented here.","The account of the local-treatment dissemination exchange is incomplete, including an additional response to physiological counterarguments and uncertainty in a relayed radiation caution's attribution. A complete account of treatment choices when surgery could not proceed after neoadjuvant therapy is also unavailable.","Many numerical results, subgroup observations and proposed explanations are reported by speakers. Detailed event adjudication, subgroup tables and full safety analyses are not available in the statements used here; these views cannot establish misclassification, a predictive subgroup or a causal mechanism.","The primary publication passage provides a conclusion, while the protocol amendment provides an interim stopping account and revised follow-up plans. Neither justifies treating every social-post numerical or mechanistic interpretation as a primary result.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Source descriptions of a speaker as presenting KEYNOTE-867 and another speaker as involved in KEYNOTE-867 are attributed descriptions of involvement, not evidence that their views are independent external assessments.","Historical statements about eligibility, treatment schedules, enrollment targets and site access are preserved as dated accounts. Differences between those accounts are not silently reconciled, and post dates do not establish meeting dates or changes of mind.","Comparisons with I-SABR, S1914, surgical studies and other radiation–immunotherapy experiences involve different regimens, populations or endpoints. They explain speakers' reasoning but do not establish comparative efficacy between those alternatives."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":3,"other":0,"podcast":0,"publication":1,"registry":1,"regulatory":0,"x_thread":50,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":55,"context":1,"methods":1},"count":57,"evidence_window":{"end":"2026-10-30","start":"2020-04-23"},"retrieval_snapshot":"2026-10-31T06:22:18.046072Z","timeline":[{"count":2,"week":"2020-W17"},{"count":1,"week":"2020-W51"},{"count":1,"week":"2021-W20"},{"count":1,"week":"2021-W49"},{"count":1,"week":"2022-W02"},{"count":2,"week":"2022-W03"},{"count":1,"week":"2022-W04"},{"count":1,"week":"2022-W44"},{"count":2,"week":"2022-W45"},{"count":1,"week":"2022-W46"},{"count":1,"week":"2023-W24"},{"count":1,"week":"2023-W33"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2023-W43"},{"count":1,"week":"2024-W20"},{"count":1,"week":"2024-W31"},{"count":18,"week":"2024-W35"},{"count":2,"week":"2024-W36"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2024-W49"},{"count":6,"week":"2024-W50"},{"count":1,"week":"2024-W51"},{"count":2,"week":"2025-W23"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W14"},{"count":1,"week":"2026-W32"},{"count":2,"week":"2026-W37"},{"count":1,"week":"2026-W40"},{"count":2,"week":"2026-W41"},{"count":4,"week":"2026-W44"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT03924869:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03924869:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03924869:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03924869:sap:1","quote_policy":"short_quote_link_out"},{"id":"pubmed:39298144","quote_policy":"short_quote_link_out"},{"id":"pubmed:42950173","quote_policy":"short_quote_link_out"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47nm5qperrpmcqdmzxt3qgec-3mz3qdjooj225","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-fraujaa5htqy5foevaon4ccn-3lcbomiupok2v","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kfntsbhjami25nva6eva35bt-3l2u44h4mqt2c","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ulozjjf5jrge3s4yr7luulgu-3lcviun4ijs2y","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7272744162762870784","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7273002932323729409","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7513569196811694081","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1120691318584500225:83883058-7730-43bc-a34c-aa958b1f2bf6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1120700365031165952:fa174e01-5961-4478-9275-7705466156a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1120798064086867969:23e7faf0-da76-4501-958e-e2d0cbd351f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1253305079068835840:e8f3b949-bc14-4b7d-a2d7-90453852bf65","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1253386294711005185:abfb1322-3517-44f5-af8e-13f7838c1526","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1339636950974787584:16d6464b-8208-4068-8f54-d613d029df04","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1395092533739278336:2d84d880-f7b0-43ca-af14-1983a3fb550f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1401355803957805061:9bf8dc60-afee-43de-b04c-4138c6fc8560","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1424573444931260424:398fde86-9a4b-4f00-90d0-b331f44ce932","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1480365169960181766:c327c043-12f6-4687-9b98-76eb0e208723","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1483779022358151168:ec7ca95b-9080-41ff-9c4d-f0f6c5498837","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1485977545161981953:11824e8c-a9c6-47be-a0e1-e76b1b2f5ddf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533819842939310080:e1912fe9-b560-411c-b70c-2de7c71a9efd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1584576241419812864:6d17a7c0-d6f7-4a09-9170-7522782cc7e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1589785929275019264:03fc5231-2b70-4904-a043-47cefaefaf8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1591475676003323904:901705e0-d0f1-4322-a338-2d2880cb8219","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1619340715867389952:82afdd9a-b40e-43b8-9fdc-fa7ef187288c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1643640797739249666:2040f828-a661-4f4d-af92-62f3f0473620","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1660282033187201025:6dfd7c0a-2679-4777-9369-a17a2cf4e4cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1669343760625573896:f0dd9345-9f88-4dfb-a327-7793cce0a588","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1671982184410783766:e543d4d8-91be-4879-9121-5bcf84eea169","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1692668665726947425:2ea155bb-8517-4442-945b-433f60626d0c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701819838858154219:35f1bc50-d128-407b-a46b-77bb35fcb22d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716064358839509376:f7af6dd2-5a23-44ca-a60b-6666b193918a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1750253894981316702:4829602e-ba18-4e0d-a468-956ab292882e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1771758691076931645:c5e2d07b-0536-4e0e-96c0-853fa5e6adb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1789984338873819298:35becdc2-dfe7-46e7-98f2-4d94c5e558e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1819735978598363593:48e95362-4959-4775-8539-ad4eb3127251","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829104605764153485:bf6d432b-ac0c-4c1b-a990-eb0fe94ef6a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829105221139562813:7cb84bf5-cfa0-48ba-8d62-3547b5ee2f7c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829106272706420783:c867284f-d0f0-4213-853c-d609b9cb2646","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829107031191470421:30a4e2b7-a279-48d4-abc8-66718ef09188","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829107130508407159:c3f4290c-fce3-4c5b-af56-6c52f8711f6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829109322170687676:19d0b078-27c8-4a0b-815c-e6c7d82dfca4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829139603389022705:8dbcea1b-09f6-4f83-8915-33f4e3ecd679","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829158472958783674:0ab11619-df78-4315-add7-1df36afd791b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829172958327177600:3f4a2e3f-9724-4dd4-9e4e-d067fbf98fcd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829180488394895567:4d36db04-31c1-4f21-8877-a3e4f5b025dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829222890547405005:a15263a7-2ad0-4c07-b024-49227dcb183d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829238787656040795:9b7af23b-6dab-48b5-80ff-06b66264d50a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829258902434685319:ed416ad5-6703-4e16-9d2b-3f8fe95084c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829279717427712026:db86b426-6084-4419-8c42-a7b850463bb8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829287608876421245:306b7148-5a40-4939-ad98-d47210d7663a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829342225471283707:f4f9638f-ce5e-4959-b8f4-2d3132e3b40c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829379807852822583:6cd777b6-2603-4f54-8afd-73b8111e43d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829522340360999370:15ee572a-a00b-4332-a330-6f93728332ca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829534541100532001:497aaab2-ce0e-41c5-99b5-6343341d2149","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829557199279968289:a4dd5383-8970-4e34-8f16-75b1055e458f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829651061818470712:33a87e8e-c113-42d4-91d6-1c09a17fe0b5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829651478795207122:0f5759b4-1d42-4158-8b20-6e13cee021d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829749759705563576:c88794d0-fdf6-43f8-bca2-5e73db9d37c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829755707450634487:719b3bfa-c6c5-485a-b36e-a8273e12f756","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829863979755213162:0c553b42-a7cf-4bc7-ac96-d3ef5cee5df3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829933920038625541:9be60373-21df-434d-bb3d-3c144b16d924","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1830061971137577081:fabf1941-8c4d-413b-8001-2a75a5822f6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1831031218156326985:18cfab6f-314d-424e-8ec1-b5188c1accda","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1831180391442780263:49d67066-f65d-4bdd-96f9-7ada2e3189a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832798597080830314:48f24207-4508-4f38-9f23-92facc865e98","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833575070704537734:370ed12a-c468-4f6a-af47-eae1ba6e8dbf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833732338414497837:139fbe4d-9a67-4e68-b65f-90fce8a28a81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834457036358111373:43bc98f4-74e5-4baa-b5e2-b3b8f64153a8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1839770132106838260:f51c969f-0ee4-469e-bcca-77ff4d6bdea7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1841179210242802152:37d90b00-12c2-402d-a8b6-50e2d09f6402","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1863352648688107749:d3535e52-4588-45eb-b07b-f809496a6021","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865803769772146863:ef0957dc-6ef6-4d9c-aad3-fde72ecc0ee3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866188564968432096:0af1a116-8705-46d9-8177-882ea0f5380c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866875688701006247:3b7de05e-50af-4868-8499-343c60c6c086","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866992907716268061:58f2b776-2550-45fd-9f7f-724039bebab6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1867714541876130107:95d24526-1dea-4cc5-9ee7-8b9deb0a1856","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929649005186748786:13978dda-6cf7-4285-b49e-311fc1e301c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929649637910368575:a44a1804-da72-46b1-b157-3c6d29dba786","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929656000853754063:efb06ddc-5896-465b-a310-10ba00ab812d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2025608644013035895:b0d8e254-3ca8-4e2d-9b45-494e03261371","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084965141636845619:441e1c87-91cf-4441-b0c5-43f165436dea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097054542986953011:3a016bda-0c6a-4507-aa23-b95b21ced5b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097082188965806550:640779bd-4ae3-4329-9d6c-f0500f1106ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098983347322339574:9ac7d680-8d58-404b-8f0b-d4cb8703ec12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106699612870549668:75e09341-b831-4450-8759-561295efca5c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115536983649026393:c3489795-4122-42f3-90c0-d12b1aaf1a94","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115580480519344354:908b15be-d7dc-4ae9-bcd7-ef756c8efb24","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115602905805783251:0c12d72e-e7b3-49de-9d84-3e3950d392e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115613474860749085:a95c507b-afb4-4f71-9a79-0f91269bb0d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115775658286584002:8c40c86c-a09d-476e-b952-ede9a4628abf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115824739256263119:7f15dd49-dc66-4484-ae0f-fb9a1cff754a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115900922899714143:74781997-089e-4588-aa19-12ab1c772ac2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116138749071651326:7331b5bc-f11b-4647-8cc0-d30ad8b4e04f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116301969468084610:72c28efb-f3fd-4313-8c8c-82276edd2b89","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:BPiy7mn_Nho","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:mbR3ToZ1ZJg","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":3,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":87,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":96},"count":96,"evidence_window":{"end":"2026-10-30","start":"2019-04-23"},"retrieval_snapshot":"2026-10-31T06:22:18.046072Z","timeline":[{"count":3,"week":"2019-W17"},{"count":2,"week":"2020-W17"},{"count":1,"week":"2020-W51"},{"count":1,"week":"2021-W20"},{"count":1,"week":"2021-W22"},{"count":1,"week":"2021-W32"},{"count":1,"week":"2021-W49"},{"count":1,"week":"2022-W02"},{"count":2,"week":"2022-W03"},{"count":1,"week":"2022-W04"},{"count":1,"week":"2022-W23"},{"count":1,"week":"2022-W43"},{"count":1,"week":"2022-W44"},{"count":2,"week":"2022-W45"},{"count":1,"week":"2022-W46"},{"count":1,"week":"2023-W04"},{"count":1,"week":"2023-W14"},{"count":1,"week":"2023-W20"},{"count":1,"week":"2023-W24"},{"count":1,"week":"2023-W25"},{"count":1,"week":"2023-W33"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2023-W43"},{"count":1,"week":"2024-W04"},{"count":1,"week":"2024-W12"},{"count":1,"week":"2024-W20"},{"count":1,"week":"2024-W31"},{"count":29,"week":"2024-W35"},{"count":4,"week":"2024-W36"},{"count":3,"week":"2024-W37"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2024-W40"},{"count":2,"week":"2024-W48"},{"count":1,"week":"2024-W49"},{"count":8,"week":"2024-W50"},{"count":1,"week":"2024-W51"},{"count":3,"week":"2025-W23"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W14"},{"count":1,"week":"2026-W32"},{"count":3,"week":"2026-W37"},{"count":1,"week":"2026-W40"},{"count":2,"week":"2026-W41"},{"count":10,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"KEYNOTE-867","aliases":["KEYNOTE-867","MK-3475-867/KEYNOTE-867","Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)","A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)"],"brief_title":"Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Small Cell Lung Cancer"],"display_condition":"unresected stage I/II non-small cell lung cancer","display_interventions":[["pembrolizumab"]],"enrollment":{"count":448,"type":"ACTUAL"},"interventions":[{"name":"Stereotactic Body Radiotherapy (SBRT)","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"},{"name":"Pembrolizumab","synonyms":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT03924869","official_title":"A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)","overall_status":"TERMINATED","phase":["PHASE3"],"primary_completion_date":{"date":"2024-06-11","type":"ACTUAL"},"primary_endpoints":[{"description":"EFS was defined as the time from randomization to the first occurrence of any of the following events: 1) local, regional, or distant recurrence of disease as assessed by radiographic recurrence by blinded independent central review (BICR), positive pathology by local assessment, physical examination by local assessment confirmed by positive pathology and/or radiographic recurrence by BICR, OR 2) death due to any cause. EFS was reported for each arm.","measure":"Event-free Survival (EFS)","timeFrame":"Up to approximately 56.8 months"}],"registered_date":{"date":"2019-04-23","type":"ACTUAL"},"registry_last_updated":"2025-12-11","registry_url":"https://clinicaltrials.gov/study/NCT03924869","short_name":"KEYNOTE-867","short_name_basis":"canonical_name","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2019-06-25","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"3475-867","type":"sponsor_study_id"},{"domain":"MSD","id":"MK-3475-867","type":"other"},{"domain":"MSD","id":"KEYNOTE-867","type":"other"},{"domain":"JAPAC-CTI","id":"194909","type":"registry"},{"domain":"EU CT","id":"2022-500413-11-00","type":"registry"},{"domain":"UTN","id":"U1111-1275-8515","type":"registry"},{"id":"2018-004320-11","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}